| Dana Mathew, MD | |
|
1350 Hickory St, Melbourne, FL 32901-3224 | |
| (321) 434-7000 | |
| Not Available |
| Full Name | Dana Mathew |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 18 Years |
| Location | 1350 Hickory St, Melbourne, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073734356 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | ME128175 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Palm Bay Hospital | Palm bay, FL | Hospital |
| Holmes Regional Medical Center | Melbourne, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brevard Physician Associates Pllc | 1850535048 | 199 |
News Archive
RaySearch Laboratories AB announces today that the license agreement with Varian Medical Systems has been restructured to add one new product, strengthen the collaborative product development efforts, and make it easier to add new capabilities and features to Varian's Eclipse™ treatment planning system. Eclipse software currently incorporates three RaySearch developments, including tools for biological evaluation, biological optimization, and conformal optimization.
With help from a common aquarium pet and a recently released online database of human genetic variation, a collaborative team of Penn State researchers has found what could be the most important skin color gene identified to date.
An Australian company is set to challenge the boundaries of drug discovery in Australia with the unveiling of the nation's top drug discovery facility by Western Australian Minister for State Development, Clive Brown.
A group of researchers at Osaka University elucidated how a gene named Ly6/Plaur domain containing 8 (Lypd8) inhibits bacterial invasion of colonic epithelia, regulating intestinal inflammation. This achievement may lead to the development of drugs for ulcerative colitis.
PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD). These data were presented at the International Congress of the World Muscle Society in Kumamoto, Japan and will be the basis of interactions with the U.S. Food and Drug Administration (FDA) and national regulatory authorities in Europe in the fourth quarter of 2010.
› Verified 9 days ago
| Entity Name | Brevard Physician Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598008955 PECOS PAC ID: 1850535048 Enrollment ID: O20130909000619 |
News Archive
RaySearch Laboratories AB announces today that the license agreement with Varian Medical Systems has been restructured to add one new product, strengthen the collaborative product development efforts, and make it easier to add new capabilities and features to Varian's Eclipse™ treatment planning system. Eclipse software currently incorporates three RaySearch developments, including tools for biological evaluation, biological optimization, and conformal optimization.
With help from a common aquarium pet and a recently released online database of human genetic variation, a collaborative team of Penn State researchers has found what could be the most important skin color gene identified to date.
An Australian company is set to challenge the boundaries of drug discovery in Australia with the unveiling of the nation's top drug discovery facility by Western Australian Minister for State Development, Clive Brown.
A group of researchers at Osaka University elucidated how a gene named Ly6/Plaur domain containing 8 (Lypd8) inhibits bacterial invasion of colonic epithelia, regulating intestinal inflammation. This achievement may lead to the development of drugs for ulcerative colitis.
PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD). These data were presented at the International Congress of the World Muscle Society in Kumamoto, Japan and will be the basis of interactions with the U.S. Food and Drug Administration (FDA) and national regulatory authorities in Europe in the fourth quarter of 2010.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dana Mathew, MD 925 Bennington Dr, Rm 1107g W Wing, Raleigh, NC 27615-1206 Ph: (919) 937-7198 | Dana Mathew, MD 1350 Hickory St, Melbourne, FL 32901-3224 Ph: (321) 434-7000 |
News Archive
RaySearch Laboratories AB announces today that the license agreement with Varian Medical Systems has been restructured to add one new product, strengthen the collaborative product development efforts, and make it easier to add new capabilities and features to Varian's Eclipse™ treatment planning system. Eclipse software currently incorporates three RaySearch developments, including tools for biological evaluation, biological optimization, and conformal optimization.
With help from a common aquarium pet and a recently released online database of human genetic variation, a collaborative team of Penn State researchers has found what could be the most important skin color gene identified to date.
An Australian company is set to challenge the boundaries of drug discovery in Australia with the unveiling of the nation's top drug discovery facility by Western Australian Minister for State Development, Clive Brown.
A group of researchers at Osaka University elucidated how a gene named Ly6/Plaur domain containing 8 (Lypd8) inhibits bacterial invasion of colonic epithelia, regulating intestinal inflammation. This achievement may lead to the development of drugs for ulcerative colitis.
PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD). These data were presented at the International Congress of the World Muscle Society in Kumamoto, Japan and will be the basis of interactions with the U.S. Food and Drug Administration (FDA) and national regulatory authorities in Europe in the fourth quarter of 2010.
› Verified 9 days ago
Corey Alvarez, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1775 W Hibiscus Blvd Ste 215, Melbourne, FL 32901 Phone: 321-837-3820 | |
Milton Smith, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 250 N Wickham Rd, Melbourne, FL 32935 Phone: 800-476-8646 Fax: 919-382-3210 | |
Dr. Elisha Anne Montgomery, MBBS Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1775 W. Hibiscus Blvd St 215, Melbourne, FL 32901 Phone: 213-802-6860 | |
Dr. Marty R Brown, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1350 S Hickory Street, Melbourne, FL 32901 Phone: 321-254-6218 Fax: 321-254-6218 | |
Johnny J Vazquez, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1350 S Hickory Street, Melbourne, FL 32901 Phone: 321-254-6218 Fax: 321-254-6230 | |
Vinay K Mehindru, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2080 W Eau Gallie Blvd, Suite A, Melbourne, FL 32935 Phone: 321-254-6218 Fax: 321-254-6230 |